Looking to RNAi, Ag-bio Field Faces Hurdles Similar to Those in Drug Development | GenomeWeb

Although it has not embraced RNAi to the same degree as drug developers, agricultural biotech firms are increasingly interested in harnessing the gene-silencing technology to improve the yields of crop plants and to enhance their resistance to pests and environmental stressors, according to one industry insider.

Yet because of its relative nascence, ag-bio RNAi faces a number of challenges to its widespread application in the space, the greatest of which being what had long stymied the technology's use in human therapeutics — delivery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.